In fiscal 2018, the Company generated $249,000 of federal research and development tax credits (“R&D Credits”), all of which were used. In fiscal 2019, the Company generated $241,000 of R&D Credits, all of which were used. There were no R&D Credits carryforwards as of September 30, 2019.
As of September 30, 2017, the Company had $155,000 in Florida state research and development tax credits (“Florida R&D Credits”) carryforwards. The Company received additional Florida R&D Credits of $25,000 in fiscal 2018 and used $93,000, leaving $87,000 of Florida R&D Credits carryforwards as of September 30, 2018, which are included in net deferred and other income tax liabilities of $(2,640,000) at September 30, 2018. The Company did not receive any additional Florida R&D Credits in fiscal 2019. The Company used the $87,000 of Florida R&D Credits carryforwards from fiscal 2018 in fiscal 2019. There were no Florida R&D Credits carryforwards at September 30, 2019.
Net income for the year ended September 30, 2019 was $10,196,000 or $0.69 per diluted share versus net income of $12,694,000 or $0.86 per diluted share for the year ended September 30, 2018. The decrease in net income was primarily due to the reduced net revenues.
Liquidity and Capital Resources
The Company generates capital resources through operations and returns on its investments.
The Company had no long-term debt outstanding at September 30, 2019 or 2018. As of September 30, 2019, the Company has funded $135,000 in cash deposits at insurance companies to cover collateral needs.
As of September 30, 2019, the Company had $10.3 million in cash and cash equivalents, and $105.3 million in marketable securities. The marketable securities are invested through professional investment management firms. The securities may be liquidated at any time into cash and cash equivalents.
The Company’s backlog, which includes orders received through the filing date of this Report, was $36.9 million at September 30, 2019 versus $43.8 million at September 30, 2018. The Company’s working capital was $150.4 million at September 30, 2019 versus $139.7 million at September 30, 2018.
The significant purchases, sales and maturities of marketable securities shown on the consolidated statements of cash flows reflect the frequent purchase and sale of United States treasury bills.
Year ended September 30, 2019 compared with the year ended September 30, 2018
Cash provided by operations in fiscal 2019 was $4,163,000, primarily resulting from net income. The increase in inventories of $3.5 million reflected the impact of a summer stock build to meet the anticipated increased demand for the Company’s products at the start of fiscal 2020. The increase in costs and estimated earnings in excess of billings of $1.9 million reflects the ongoing progress on customer contracts with revenues recognized over time prior to final billing and payment of amounts due in advance of shipment. Customer deposits decreased $2.6 million, reflecting the application of down payments on these jobs.
Cash used in operations in fiscal 2018 of $(11,997,000) was primarily due to investing an additional $15.0 million of operating cash in marketable equity securities. The increase in costs and estimated earnings in excess of billings of $5.1 million reflected significant progress on customer contracts with revenues recognized over time prior to final billing and payment of amounts due in advance of shipment. Similarly, customer deposits decreased $4.1 million, reflecting the application of down payments on these jobs.
Cash used in investing activities during the year ended September 30, 2019 of $2,104,000 and $3,550,000 for the year ended September 30, 2018, related primarily to capital expenditures for manufacturing equipment. Cash provided by financing activities of $231,000 in fiscal 2019 and $626,000 in fiscal 2018 related to proceeds from the exercise of stock options.
16